{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T13:57:56Z","timestamp":1781099876319,"version":"3.54.1"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-026-05966-x","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:32:30Z","timestamp":1781091150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CRISPR-Based Gene Therapy for Brain Disease"],"prefix":"10.1007","volume":"63","author":[{"given":"Fatemeh","family":"Khajouei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Ghaemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Abnous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mohammad","family":"Taghdisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ramezani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Alibolandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"5966_CR1","volume-title":"Global status report on neurology","author":"Organization WH","year":"2025","unstructured":"Organization WH (2025) Global status report on neurology. World Health Organization"},{"key":"5966_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102488","volume":"101","author":"Y Jing","year":"2024","unstructured":"Jing Y, Haeger A, Boumezbeur F, Binkofski F, Reetz K, Romanzetti S (2024) Neuroenergetic alterations in neurodegenerative diseases: a systematic review and meta-analysis of in vivo 31P-MRS studies. Ageing Res Rev 101:102488","journal-title":"Ageing Res Rev"},{"key":"5966_CR3","volume":"111","author":"HK Meshram","year":"2025","unstructured":"Meshram HK, Gupta SK, Gupta A, Nagori K (2025) Next-generation CRISPR gene editing tools in the precision treatment of Alzheimer\u2019s and Parkinson\u2019s disease. JARR 111:102851","journal-title":"JARR"},{"key":"5966_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116691","volume":"175","author":"N Naimi","year":"2024","unstructured":"Naimi N, Seyedmirzaei H, Hassannejad Z, Khaboushan AS (2024) Advanced nanoparticle strategies for optimizing RNA therapeutic delivery in neurodegenerative disorders. Biomed Pharmacother 175:116691","journal-title":"Biomed Pharmacother"},{"key":"5966_CR5","volume":"7","author":"M Iyer","year":"2024","unstructured":"Iyer M, Elangovan A, Sennimalai R, Babu HWS, Thiruvenkataswamy S, Krishnan J, Yadav MK, Gopalakrishnan AV, et al. (2024) Chitosan\u2013an alternative drug delivery approach for neurodegenerative diseases. Carbohydr Polym Technol Appl 7:100460","journal-title":"Carbohydr Polym Technol Appl"},{"key":"5966_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2025.1578138","volume":"19","author":"MS Khan","year":"2025","unstructured":"Khan MS, Qureshi N, Khan R, Son Y-O, Maqbool T (2025) CRISPR\/Cas9-based therapeutics as a promising strategy for management of Alzheimer\u2019s disease: progress and prospects. Front Cell Neurosci 19:1578138","journal-title":"Front Cell Neurosci"},{"issue":"13","key":"5966_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310809","volume":"24","author":"AV Ciurea","year":"2023","unstructured":"Ciurea AV, Mohan AG, Covache-Busuioc R-A, Costin H-P, Glavan L-A, Corlatescu A-D, Saceleanu VM (2023) Unraveling molecular and genetic insights into neurodegenerative diseases: advances in understanding Alzheimer\u2019s, Parkinson\u2019s, and Huntington\u2019s diseases and amyotrophic lateral sclerosis. Int J Mol Sci 24(13):10809","journal-title":"Int J Mol Sci"},{"key":"5966_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2024.105338","volume":"92","author":"AA Aljabali","year":"2024","unstructured":"Aljabali AA, El-Tanani M, Tambuwala MM (2024) Principles of CRISPR-Cas9 technology: advancements in genome editing and emerging trends in drug delivery. Journal of Drug Delivery Science and Technology 92:105338","journal-title":"Journal of Drug Delivery Science and Technology"},{"issue":"6096","key":"5966_CR9","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"6096","unstructured":"Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier EA (6096) A programmable dual-RNA\u2013guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096):816\u2013821","journal-title":"Science"},{"issue":"7785","key":"5966_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"7785","unstructured":"Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, Chen PJ, Wilson C, et al. (7785) Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576(7785):149\u2013157","journal-title":"Nature"},{"issue":"7603","key":"5966_CR11","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR (2016) Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533(7603):420\u2013424","journal-title":"Nature"},{"issue":"4","key":"5966_CR12","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.neuron.2017.10.004","volume":"96","author":"J Nishiyama","year":"2017","unstructured":"Nishiyama J, Mikuni T, Yasuda RJN (2017) Virus-mediated genome editing via homology-directed repair in mitotic and postmitotic cells in mammalian brain. Neuron 96(4):755-768. e755","journal-title":"Neuron"},{"key":"5966_CR13","doi-asserted-by":"publisher","unstructured":"Aderinto N, Olatunji G, Kokori E, Yusuf IA, Abdulrahmon M, Egbunu E, Adefusi TO, Obasanjo OM et al (2025) CRISPR-Cas9 gene editing in neuropsychiatric disorders: challenges and promising avenues. Brain Disord 100304. https:\/\/doi.org\/10.1016\/j.dscb.2025.100304","DOI":"10.1016\/j.dscb.2025.100304"},{"key":"5966_CR14","first-page":"567","volume":"22","author":"JN Nojadeh","year":"2023","unstructured":"Nojadeh JN, Eryilmaz NSB, Erg\u00fcder B\u0130 (2023) CRISPR\/Cas9 genome editing for neurodegenerative diseases. EXCLI J 22:567","journal-title":"EXCLI J"},{"issue":"1","key":"5966_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev.biochem.052308.093131","volume":"79","author":"MR Lieber","year":"2010","unstructured":"Lieber MR (2010) The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem 79(1):181\u2013211","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"5966_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1146\/annurev-med-081117-010451","volume":"70","author":"Y-L Min","year":"2019","unstructured":"Min Y-L, Bassel-Duby R (2019) CRISPR correction of Duchenne muscular dystrophy. Annu Rev Med 70(1):239\u2013255","journal-title":"Annu Rev Med"},{"issue":"9","key":"5966_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23094653","volume":"23","author":"VE Provasek","year":"2022","unstructured":"Provasek VE, Mitra J, Malojirao VH, Hegde ML (2022) DNA double-strand breaks as pathogenic lesions in neurological disorders. Int J Mol Sci 23(9):4653","journal-title":"Int J Mol Sci"},{"issue":"2","key":"5966_CR18","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.gendis.2019.12.007","volume":"8","author":"H Mollanoori","year":"2021","unstructured":"Mollanoori H, Rahmati Y, Hassani B, Mehr MH, Teimourian S (2021) Promising therapeutic approaches using CRISPR\/Cas9 genome editing technology in the treatment of Duchenne muscular dystrophy. Genes Dis 8(2):146\u2013156","journal-title":"Genes Dis"},{"issue":"1","key":"5966_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/nat.2013.0461","volume":"24","author":"K Siva","year":"2014","unstructured":"Siva K, Covello G, Denti MA (2014) Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases. Nucleic Acid Ther 24(1):69\u201386","journal-title":"Nucleic Acid Ther"},{"issue":"4","key":"5966_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/jpm8040038","volume":"8","author":"KRQ Lim","year":"2018","unstructured":"Lim KRQ, Yoon C, Yokota T (2018) Applications of CRISPR\/Cas9 for the treatment of Duchenne muscular dystrophy. J Pers Med 8(4):38","journal-title":"J Pers Med"},{"key":"5966_CR21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.addr.2015.05.008","volume":"87","author":"R Kole","year":"2015","unstructured":"Kole R, Krieg AM (2015) Exon skipping therapy for Duchenne muscular dystrophy. Adv Drug Deliv Rev 87:104\u2013107","journal-title":"Adv Drug Deliv Rev"},{"issue":"6410","key":"5966_CR22","first-page":"86","volume":"362","author":"L Amoasii","year":"2018","unstructured":"Amoasii L, Hildyard JC, Li H, Sanchez-Ortiz E, Mireault A, Caballero D, Harron R, Stathopoulou T-R, et al. (2018) Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. JS 362(6410):86\u201391","journal-title":"JS"},{"issue":"418","key":"5966_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan8081","volume":"9","author":"L Amoasii","year":"2017","unstructured":"Amoasii L, Long C, Li H, Mireault AA, Shelton JM, Sanchez-Ortiz E, McAnally JR, Bhattacharyya S, et al. (2017) Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy. Sci Transl Med 9(418):eaan8081","journal-title":"Sci Transl Med"},{"issue":"1","key":"5966_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7244","volume":"6","author":"DG Ousterout","year":"2015","unstructured":"Ousterout DG, Kabadi AM, Thakore PI, Majoros WH, Reddy TE, Gersbach CA (2015) Multiplex CRISPR\/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat Commun 6(1):6244","journal-title":"Nat Commun"},{"issue":"1","key":"5966_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/srep37051","volume":"6","author":"I Maggio","year":"2016","unstructured":"Maggio I, Liu J, Janssen JM, Chen X, Gon\u00e7alves MA (2016) Adenoviral vectors encoding CRISPR\/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells. Sci Rep 6(1):37051","journal-title":"Sci Rep"},{"key":"5966_CR26","first-page":"185","volume":"181","author":"JK Karapurkar","year":"2021","unstructured":"Karapurkar JK, Antao AM, Kim K-S, Ramakrishna SJ (2021) CRISPR-Cas9 based genome editing for defective gene correction in humans and other mammals. Pimb, science t 181:185\u2013229","journal-title":"Pimb, science t"},{"key":"5966_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.579062","volume":"14","author":"F Duarte","year":"2020","unstructured":"Duarte F, D\u00e9glon N (2020) Genome editing for CNS disorders. Front Neurosci 14:579062","journal-title":"Front Neurosci"},{"key":"5966_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102344","author":"H Liao","year":"2024","unstructured":"Liao H, Wu J, VanDusen NJ, Li Y (2024) CRISPR-Cas9-mediated homology-directed repair for precise gene editing. Mol Ther Nucleic Acids. https:\/\/doi.org\/10.1016\/j.omtn.2024.102344","journal-title":"Mol Ther Nucleic Acids"},{"issue":"2","key":"5966_CR29","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.gendis.2023.03.017","volume":"11","author":"H Jiang","year":"2024","unstructured":"Jiang H, Tang M, Xu Z, Wang Y, Li M, Zheng S, Zhu J, Lin Z, et al. (2024) <article-title update=\"added\">CRISPR\/Cas9 system and its applications in nervous system diseases. Genes Dis 11(2):675\u2013686","journal-title":"Genes Dis"},{"key":"5966_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fgeed.2025.1553590","volume":"7","author":"J-J Cabr\u00e9-Romans","year":"2025","unstructured":"Cabr\u00e9-Romans J-J, Cuella-Martin R (2025) CRISPR-dependent base editing as a therapeutic strategy for rare monogenic disorders. Front Genome Ed 7:1553590","journal-title":"Front Genome Ed"},{"issue":"22","key":"5966_CR31","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1056\/NEJMoa2504747","volume":"392","author":"K Musunuru","year":"2025","unstructured":"Musunuru K, Grandinette SA, Wang X, Hudson TR, Briseno K, Berry AM, Hacker JL, Hsu A, et al. (2025) Patient-specific in vivo gene editing to treat a rare genetic disease. N Engl J Med 392(22):2235\u20132243","journal-title":"N Engl J Med"},{"issue":"17","key":"5966_CR32","doi-asserted-by":"publisher","first-page":"6240","DOI":"10.3390\/ijms21176240","volume":"21","author":"A Kantor","year":"2020","unstructured":"Kantor A, McClements ME (2020) CRISPR-Cas9 DNA base-editing and prime-editing. Int J Mol Sci 21(17):6240, 6240","journal-title":"Int J Mol Sci"},{"issue":"5","key":"5966_CR33","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.cell.2024.01.042","volume":"187","author":"M Pacesa","year":"2024","unstructured":"Pacesa M, Pelea O, Jinek MP (2024) Past, present, and future of CRISPR genome editing technologies. Cell 187(5):1076\u20131100","journal-title":"Cell"},{"issue":"1","key":"5966_CR34","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.gendis.2023.02.027","volume":"11","author":"M Khoshandam","year":"2024","unstructured":"Khoshandam M, Soltaninejad H, Mousazadeh M, Hamidieh AA, Hosseinkhani S (2024) Clinical applications of the CRISPR\/Cas9 genome-editing system: delivery options and challenges in precision medicine. Genes Dis 11(1):268\u2013282","journal-title":"Genes Dis"},{"issue":"2","key":"5966_CR35","first-page":"1725","volume":"83","author":"M Shukla","year":"2025","unstructured":"Shukla M, Narayan MJ (2025) Proteostasis and its role in disease development. Cb, biophysics 83(2):1725\u20131741","journal-title":"Cb, biophysics"},{"key":"5966_CR36","doi-asserted-by":"crossref","unstructured":"Samelson AJ, Ariqat N, McKetney J, Rohanitazangi G, Bravo CP, Bose RS, Travaglini KJ, Lam VL, Goodness D, Ta TJC (2023) CRISPR screens in iPSC-derived neurons reveal principles of tau proteostasis.","DOI":"10.1101\/2023.06.16.545386"},{"issue":"5594","key":"5966_CR37","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1126\/science.1074069","volume":"298","author":"D Selkoe","year":"2002","unstructured":"Selkoe D (2002) Alzheimer\u2019s disease is a synaptic failure. Science 298(5594):789\u2013791","journal-title":"Science"},{"key":"5966_CR38","doi-asserted-by":"crossref","unstructured":"Chen F, Fang S, Du Y, Ghosh A, Reed MN, Long Y, Suppiramaniam V, Tang S et al (2021) CRISPR\/Cas9-mediated CysLT1R deletion reverses synaptic failure, amyloidosis and cognitive impairment in APP\/PS1 mice. Aging Albany NY 13(5):6634","DOI":"10.18632\/aging.202501"},{"issue":"1","key":"5966_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01839-8","volume":"9","author":"Y Zong","year":"2024","unstructured":"Zong Y, Li H, Liao P, Chen L, Pan Y, Zheng Y, Zhang C, Liu D, et al. (2024) Mitochondrial dysfunction: mechanisms and advances in therapy. Signal Transduct Target Ther 9(1):124","journal-title":"Signal Transduct Target Ther"},{"key":"5966_CR40","first-page":"575","volume":"30","author":"H Khan","year":"2025","unstructured":"Khan H, Riaz H, Ahmed A, Kiyani MM, Jawad SM, Shah SSUD, Abualait T, Al-Hussain F, et al. (2025) CRISPR\/Cas9 a genomic engineering technology for treatment in ALS mouse models. RT 30:575\u2013583","journal-title":"RT"},{"issue":"1","key":"5966_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47010008","volume":"47","author":"ME Kim","year":"2024","unstructured":"Kim ME, Lee JS (2024) Mechanisms and emerging regulators of neuroinflammation: exploring new therapeutic strategies for neurological disorders. Curr Issues Mol Biol 47(1):8","journal-title":"Curr Issues Mol Biol"},{"issue":"4","key":"5966_CR42","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s11481-019-09849-y","volume":"14","author":"SP Raikwar","year":"2019","unstructured":"Raikwar SP, Kikkeri NS, Sakuru R, Saeed D, Zahoor H, Premkumar K, Mentor S, Thangavel R, et al. (2019) Next generation precision medicine: CRISPR-mediated genome editing for the treatment of neurodegenerative disorders. J Neuroimmune Pharmacol 14(4):608\u2013641","journal-title":"J Neuroimmune Pharmacol"},{"key":"5966_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbi.2022.12.020","volume":"109","author":"M Schepers","year":"2023","unstructured":"Schepers M, Paes D, Tiane A, Rombaut B, Piccart E, van Veggel L, Gervois P, Wolfs E, et al. (2023) Selective PDE4 subtype inhibition provides new opportunities to intervene in neuroinflammatory versus myelin damaging hallmarks of multiple sclerosis. Brain Behav Immun 109:1\u201322","journal-title":"Brain Behav Immun"},{"issue":"1","key":"5966_CR44","doi-asserted-by":"publisher","first-page":"9148","DOI":"10.1038\/s41467-024-53429-5","volume":"15","author":"GJ Duncan","year":"2024","unstructured":"Duncan GJ, Ingram SD, Emberley K, Hill J, Cordano C, Abdelhak A, McCane M, Jenks JE, et al. (2024) Remyelination protects neurons from DLK-mediated neurodegeneration. Nat Commun 15(1):9148, 9148","journal-title":"Nat Commun"},{"key":"5966_CR45","doi-asserted-by":"crossref","unstructured":"Ma J, Goodwani S, Acton PJ, Buggia-Prevot V, Kesler SR, Jamal I, Mahant ID, Liu Z et al (2021) Inhibition of dual leucine zipper kinase prevents chemotherapy-induced peripheral neuropathy and cognitive impairments. Pain 162(10):2599\u20132612","DOI":"10.1097\/j.pain.0000000000002256"},{"key":"5966_CR46","doi-asserted-by":"publisher","DOI":"10.1172\/JCI151803","author":"W Zhang","year":"2022","unstructured":"Zhang W, Xiao D, Li X, Zhang Y, Rasouli J, Casella G, Boehm A, Hwang D, et al. (2022) SIRT1 inactivation switches reactive astrocytes to an antiinflammatory phenotype in CNS autoimmunity. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI151803","journal-title":"J Clin Invest"},{"key":"5966_CR47","doi-asserted-by":"crossref","unstructured":"Tiane A, Schepers M, Reijnders RA, van Veggel L, Chenine S, Rombaut B, Dempster E, Verfaillie C et al (2023) From methylation to myelination: epigenomic and transcriptomic profiling of chronic inactive demyelinated multiple sclerosis lesions. Acta Neuropathol 146(2):283\u2013299","DOI":"10.1007\/s00401-023-02596-8"},{"issue":"1","key":"5966_CR48","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00726-021-03111-7","volume":"54","author":"V Martinsen","year":"2022","unstructured":"Martinsen V, Kursula P (2022) Multiple sclerosis and myelin basic protein: insights into protein disorder and disease. Amino Acids 54(1):99\u2013109","journal-title":"Amino Acids"},{"issue":"1","key":"5966_CR49","doi-asserted-by":"publisher","first-page":"8570","DOI":"10.1038\/s41467-024-52444-w","volume":"15","author":"LJ Wagstaff","year":"2024","unstructured":"Wagstaff LJ, Bestard-Cuche N, Kaczmarek M, Fidanza A, McNeil L, Franklin RJ, Williams (2024) CRISPR-edited human ES-derived oligodendrocyte progenitor cells improve remyelination in rodents. Nat Commun 15(1):8570, 8570","journal-title":"Nat Commun"},{"issue":"10","key":"5966_CR50","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/s41593-023-01432-2","volume":"26","author":"A Kendirli","year":"2023","unstructured":"Kendirli A, de la Rosa C, L\u00e4mmle KF, Eglseer K, Bauer IJ, Kavaka V, Winklmeier S, Zhuo L, et al. (2023) A genome-wide in vivo CRISPR screen identifies essential regulators of T cell migration to the CNS in a multiple sclerosis model. Nat Neurosci 26(10):1713\u20131725","journal-title":"Nat Neurosci"},{"key":"5966_CR51","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176910","author":"S Ghorbani","year":"2024","unstructured":"Ghorbani S, Li C, Lozinski BM, Moezzi D, D\u2019Mello C, Dong Y, Visser F, Li H, et al. (2024) Fibulin-2 is an extracellular matrix inhibitor of oligodendrocytes relevant to multiple sclerosis. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI176910","journal-title":"J Clin Invest"},{"key":"5966_CR52","doi-asserted-by":"crossref","unstructured":"Park H, Shin J, Kim Y, Saito T, Saido TC, Kim J (2022) CRISPR\/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer\u2019s.","DOI":"10.1186\/s40035-022-00314-0"},{"issue":"5","key":"5966_CR53","doi-asserted-by":"publisher","DOI":"10.18632\/aging.202501","volume":"13","author":"F Chen","year":"2021","unstructured":"Chen F, Fang S, Du Y, Ghosh A, Reed MN, Long Y, Suppiramaniam V, Tang S, et al. (2021) CRISPR\/Cas9-mediated CysLT1R deletion reverses synaptic failure, amyloidosis and cognitive impairment in APP\/PS1 mice. Aging (albany NY) 13(5):6634","journal-title":"Aging (albany NY)"},{"issue":"1","key":"5966_CR54","doi-asserted-by":"publisher","first-page":"5370","DOI":"10.1038\/s41467-020-19227-5","volume":"11","author":"A McQuade","year":"2020","unstructured":"McQuade A, Kang YJ, Hasselmann J, Jairaman A, Sotelo A, Coburn M, Shabestari SK, Chadarevian JP, et al. (2020) Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer\u2019s disease. Nat Commun 11(1):5370, 5370","journal-title":"Nat Commun"},{"issue":"29","key":"5966_CR55","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo3610","volume":"8","author":"N Singh","year":"2022","unstructured":"Singh N, Das B, Zhou J, Hu X, Yan (2022) Targeted BACE-1 inhibition in microglia enhances amyloid clearance and improved cognitive performance. Sci Adv 8(29):eabo3610","journal-title":"Sci Adv"},{"issue":"759","key":"5966_CR56","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adi4830","volume":"16","author":"J Han","year":"2024","unstructured":"Han J, Sul JH, Lee J, Kim E, Kim HK, Chae M, Lim J, Kim J et al (2024) Engineered exosomes with a photoinducible protein delivery system enable CRISPR-Cas\u2013based epigenome editing in Alzheimer\u2019s disease. Sci Transl Med 16(759):eadi4830","journal-title":"Sci Transl Med"},{"issue":"2","key":"5966_CR57","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3233\/JAD-171058","volume":"62","author":"DC Tan","year":"2018","unstructured":"Tan DC, Yao S, Ittner A, Bertz J, Ke YD, Ittner LM, Delerue FGoantk (2018) Generation of a new tau knockout (tau\u0394ex1) line using CRISPR\/Cas9 genome editing in mice. J Alzheimers Dis 62(2):571\u2013578","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"5966_CR58","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40035-024-00415-y","volume":"13","author":"MS Gee","year":"2024","unstructured":"Gee MS, Kwon E, Song M-H, Jeon SH, Kim N, Lee JK, Koo (2024) CRISPR base editing-mediated correction of a tau mutation rescues cognitive decline in a mouse model of tauopathy. Transl Neurodegener 13(1):21, 21","journal-title":"Transl Neurodegener"},{"issue":"2","key":"5966_CR59","doi-asserted-by":"publisher","first-page":"e12188","DOI":"10.15252\/emmm.202012188","volume":"13","author":"S Guhathakurta","year":"2021","unstructured":"Guhathakurta S, Kim J, Adams L, Basu S, Song MK, Adler E, Je G, Fiadeiro MB, et al. (2021) Targeted attenuation of elevated histone marks at SNCA alleviates \u03b1\u2010synuclein in Parkinson\u2019s disease. EMBO Mol Med 13(2):e12188","journal-title":"EMBO Mol Med"},{"key":"5966_CR60","doi-asserted-by":"publisher","first-page":"1420183","DOI":"10.3389\/fbioe.2024.1420183","volume":"12","author":"P Guzm\u00e1n-Sastoque","year":"2024","unstructured":"Guzm\u00e1n-Sastoque P, Sotelo S, Esmeral NP, Albarrac\u00edn SL, Sutachan J-J, Reyes LH, Mu\u00f1oz-Camargo C, Cruz JC, et al. (2024) Assessment of CRISPRa-mediated gdnf overexpression in an in vitro Parkinson\u2019s disease model. Front Bioeng Biotechnol 12:1420183, 1420183","journal-title":"Front Bioeng Biotechnol"},{"issue":"5","key":"5966_CR61","first-page":"e14797","volume":"14","author":"F Giesert","year":"2022","unstructured":"Giesert F, Rauser B, Lao CL, Hembach S, Lefort S, Ibarra IL, Koupourtidou C, Luecken MD, et al. (2022) Parkinson\u2019s disease motor symptoms rescue by CRISPRa\u2010reprogramming astrocytes into GABAergic neurons. EMBO Mol Med 14(5):e14797","journal-title":"EMBO Mol Med"},{"key":"5966_CR62","doi-asserted-by":"publisher","first-page":"1656729","DOI":"10.3389\/fimmu.2025.1656729","volume":"16","author":"Q Miao","year":"2025","unstructured":"Miao Q, Wang T, Wang H, Yu Y, Jin (2025) Loss of DJ-1 alleviates microglia-mediated neuroinflammation in Parkinson\u2019s disease via autophagy-lysosomal degradation of NLRP3. Front Immunol 16:1656729, 1656729","journal-title":"Front Immunol"},{"issue":"1","key":"5966_CR63","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41434-023-00414-0","volume":"31","author":"LF Narv\u00e1ez-P\u00e9rez","year":"2024","unstructured":"Narv\u00e1ez-P\u00e9rez LF, Paz-Berm\u00fadez F, Avalos-Fuentes JA, Campos-Romo A, Flor\u00e1n-Gardu\u00f1o B, Segovia J (2024) CRISPR\/sgRNA-directed synergistic activation mediator (SAM) as a therapeutic tool for Parkinson\u2019s disease. Gene Ther 31(1):31\u201344","journal-title":"Gene Ther"},{"key":"5966_CR64","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.97180.3","volume":"13","author":"D B\u00f6ck","year":"2024","unstructured":"B\u00f6ck D, Wilhelm M, Mumenthaler J, Carpanese D, Kulcs\u00e1r P, d\u2018 Aquin S, Cremonesi A, Rassi A, et al. (2024) Base editing of Ptbp1 in neurons alleviates symptoms in a mouse model of Parkinson\u2019s disease. Elife 13:RP97180 (39714464(10.7554))","journal-title":"Elife"},{"key":"5966_CR65","doi-asserted-by":"publisher","first-page":"1008827","DOI":"10.3389\/fnmol.2022.1008827","volume":"15","author":"M Zhang","year":"2022","unstructured":"Zhang M, Yi F, Wu J, Tang (2022) The efficient generation of knockout microglia cells using a dual-sgRNA strategy by CRISPR\/Cas9. Front Mol Neurosci 15:1008827, 1008827","journal-title":"Front Mol Neurosci"},{"key":"5966_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-021-02585-2","volume":"12","author":"K-H Chang","year":"2021","unstructured":"Chang K-H, Huang C-Y, Ou-Yang C-H, Ho C-H, Lin H-Y, Hsu C-L, Chen Y-T, Chou Y-C, et al. (2021) In vitro genome editing rescues parkinsonism phenotypes in induced pluripotent stem cells-derived dopaminergic neurons carrying LRRK2 p. G2019S mutation. Stem Cell Res Ther 12:1\u201318","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"5966_CR67","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/ejn.14286","volume":"49","author":"Y Chen","year":"2019","unstructured":"Chen Y, Dolt KS, Kriek M, Baker T, Downey P, Drummond NJ, Canham MA, Natalwala A, et al. (2019) Engineering synucleinopathy\u2010resistant human dopaminergic neurons by CRISPR\u2010mediated deletion of the SNCA gene. Eur J Neurosci 49(4):510\u2013524","journal-title":"Eur J Neurosci"},{"issue":"10","key":"5966_CR68","doi-asserted-by":"publisher","first-page":"bio.044347","DOI":"10.1242\/bio.044347","volume":"8","author":"SK Soman","year":"2019","unstructured":"Soman SK, Baza\u0142a M, Keatinge M, Bandmann O, Kuznicki (2019) Restriction of mitochondrial calcium overload by mcu inactivation renders a neuroprotective effect in zebrafish models of Parkinson\u2019s disease. Biol Open 8(10):bio.044347","journal-title":"Biol Open"},{"issue":"5","key":"5966_CR69","doi-asserted-by":"publisher","first-page":"e10351","DOI":"10.1002\/btm2.10351","volume":"8","author":"H Wu","year":"1917","unstructured":"Wu H, Wei J, Zhao X, Liu Y, Chen Z, Wei K, Lu J, Chen W, et al. (1917) Neuroprotective effects of an engineered Escherichia coli Nissle 1917 on Parkinson\u2019s disease in mice by delivering GLP\u20101 and modulating gut microbiota. Bioeng Transl Med 8(5):e10351","journal-title":"Bioeng Transl Med"},{"issue":"3","key":"5966_CR70","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.cell.2020.03.024","volume":"181","author":"H Zhou","year":"2020","unstructured":"Zhou H, Su J, Hu X, Zhou C, Li H, Chen Z, Xiao Q, Wang B, et al. (2020) Glia-to-neuron conversion by CRISPR-CasRx alleviates symptoms of neurological disease in mice. Cell 181(3):590-603. e516","journal-title":"Cell"},{"issue":"1","key":"5966_CR71","doi-asserted-by":"publisher","first-page":"17796","DOI":"10.1038\/s41598-023-45078-3","volume":"13","author":"D Sastre","year":"2023","unstructured":"Sastre D, Zafar F, Torres CAM, Piper D, Kirik D, Sanders LH, Qi LS, Sch\u00fcle BIS (2023) Inactive S. aureus Cas9 downregulates alpha-synuclein and reduces mtDNA damage and oxidative stress levels in human stem cell model of Parkinson\u2019s disease. Sci Rep 13(1):17796, 17796","journal-title":"Sci Rep"},{"issue":"3","key":"5966_CR72","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/brain\/awaa045","volume":"143","author":"G Colasante","year":"2020","unstructured":"Colasante G, Qiu Y, Massimino L, Di Berardino C, Cornford JH, Snowball A, Weston M, Jones SP, et al. (2020) In vivo CRISPRa decreases seizures and rescues cognitive deficits in a rodent model of epilepsy. Brain 143(3):891\u2013905","journal-title":"Brain"},{"issue":"1","key":"5966_CR73","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/ana.26656","volume":"94","author":"J Shi","year":"2023","unstructured":"Shi J, Xin H, Shao Y, Dai S, Tan N, Li Z, Fei F, Wu D, et al. (2023) CRISPR\u2010based KCC2 upregulation attenuates drug\u2010resistant seizure in mouse models of epilepsy. Ann Neurol 94(1):91\u2013105","journal-title":"Ann Neurol"},{"key":"5966_CR74","doi-asserted-by":"publisher","first-page":"104954","DOI":"10.1016\/j.nbd.2020.104954","volume":"141","author":"T Yamagata","year":"2020","unstructured":"Yamagata T, Raveau M, Kobayashi K, Miyamoto H, Tatsukawa T, Ogiwara I, Itohara S, Hensch TK, et al. (2020) CRISPR\/dCas9-based Scn1a gene activation in inhibitory neurons ameliorates epileptic and behavioral phenotypes of Dravet syndrome model mice. Neurobiol Dis 141:104954, 104954","journal-title":"Neurobiol Dis"},{"key":"5966_CR75","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jare.2024.07.018","volume":"63","author":"Q Guan","year":"2024","unstructured":"Guan Q, Wang Z, Zhang K, Liu Z, Zhou H, Cao D, Mao (2024) CRISPR\/Cas9-mediated neuronal deletion of 5-lipoxygenase alleviates deficits in mouse models of epilepsy. J Adv Res 63:73\u201390","journal-title":"J Adv Res"},{"key":"5966_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2024.106434","volume":"192","author":"Q He","year":"2024","unstructured":"He Q, Meng C, Jia M, Tan J, Huang K, Gan H, Li L, Zhao J (2024) NLRP6 deficiency inhibits neuroinflammation and ameliorates brain injury in ischemic stroke by blocking NLRs inflammasomes activation through proteasomal degradation of pro-caspase-1. Neurobiol Dis 192:106434","journal-title":"Neurobiol Dis"},{"issue":"3","key":"5966_CR77","doi-asserted-by":"publisher","first-page":"523","DOI":"10.14336\/AD.2019.0807","volume":"11","author":"X Li","year":"2020","unstructured":"Li X, Liao Y, Dong Y, Li S, Wang F, Wu R, Yuan Z, Cheng J (2020) Mib2 deficiency inhibits microglial activation and alleviates ischemia-induced brain injury. Aging Dis 11(3):523","journal-title":"Aging Dis"},{"key":"5966_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.1401038","volume":"16","author":"X Song","year":"2024","unstructured":"Song X, Lan Y, Lv S, Wang Y, Chen L, Lu T, Liu F, Peng D (2024) Downregulation of Ripk1 and Nsf mediated by CRISPR-CasRx ameliorates stroke volume and neurological deficits after ischemia stroke in mice. Front Aging Neurosci 16:1401038","journal-title":"Front Aging Neurosci"},{"key":"5966_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.577927","volume":"11","author":"K Wang","year":"2020","unstructured":"Wang K, Sun Z, Ru J, Wang S, Huang L, Ruan L, Lin X, Jin K, et al. (2020) Ablation of GSDMD improves outcome of ischemic stroke through blocking canonical and non-canonical inflammasomes dependent pyroptosis in microglia. Front Neurol 11:577927","journal-title":"Front Neurol"},{"issue":"10","key":"5966_CR80","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/cns.13699","volume":"27","author":"S Xu","year":"2021","unstructured":"Xu S, Bian H, Shu S, Xia S, Gu Y, Zhang M, Xu Y, Cao X (2021) AIM2 deletion enhances blood\u2010brain barrier integrity in experimental ischemic stroke. CNS Neurosci Ther 27(10):1224\u20131237","journal-title":"CNS Neurosci Ther"},{"issue":"1","key":"5966_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-71212-w","volume":"14","author":"Y Fukui","year":"2024","unstructured":"Fukui Y, Morihara R, Hu X, Nakano Y, Yunoki T, Takemoto M, Abe K, Yamashita T (2024) Suppression of PTBP1 in hippocampal astrocytes promotes neurogenesis and ameliorates recognition memory in mice with cerebral ischemia. Sci Rep 14(1):20521","journal-title":"Sci Rep"},{"issue":"12","key":"5966_CR82","doi-asserted-by":"publisher","DOI":"10.7150\/thno.98088","volume":"14","author":"J-Y Ryu","year":"2024","unstructured":"Ryu J-Y, Cerecedo-Lopez C, Yang H, Ryu I, Du R (2024) Brain-targeted intranasal delivery of protein-based gene therapy for treatment of ischemic stroke. Theranostics 14(12):4773","journal-title":"Theranostics"},{"issue":"3","key":"5966_CR83","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41556-020-0471-6","volume":"22","author":"X Li","year":"2020","unstructured":"Li X, Qian X, Wang B, Xia Y, Zheng Y, Du L, Xu D, Xing D, et al. (2020) Programmable base editing of mutated TERT promoter inhibits brain tumour growth. Nat Cell Biol 22(3):282\u2013288","journal-title":"Nat Cell Biol"},{"issue":"7","key":"5966_CR84","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1093\/neuonc\/noad024","volume":"25","author":"E Aquilanti","year":"2023","unstructured":"Aquilanti E, Kageler L, Watson J, Baird DM, Jones RE, Hodges M, Szegletes ZM, Doench JG, et al. (2023) Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume. Neuro-oncol 25(7):1275\u20131285","journal-title":"Neuro-oncol"},{"issue":"33","key":"5966_CR85","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202402178","volume":"11","author":"W Ruan","year":"2024","unstructured":"Ruan W, Xu S, An Y, Cui Y, Liu Y, Wang Y, Ismail M, Liu Y, et al. (2024) Brain\u2010targeted Cas12a ribonucleoprotein nanocapsules enable synergetic gene co\u2010editing leading to potent inhibition of orthotopic glioblastoma. Adv Sci 11(33):2402178","journal-title":"Adv Sci"},{"key":"5966_CR86","doi-asserted-by":"publisher","first-page":"100929","DOI":"10.1016\/j.neo.2023.100929","volume":"44","author":"X Han","year":"2023","unstructured":"Han X, Abdallah MO, Breuer P, Stahl F, Bakhit Y, Potthoff A-L, Pregler BE, Schneider M, et al. (2023) Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma. Neoplasia 44:100929, 100929","journal-title":"Neoplasia"},{"issue":"1","key":"5966_CR87","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12951-025-03112-8","volume":"23","author":"X Liu","year":"2025","unstructured":"Liu X, Liu X, Luo X, Zhu M, Liu N, Li J, Zhang Q, Zou C, et al. (2025) Synergistic strategies for glioblastoma treatment: CRISPR-based multigene editing combined with immune checkpoint blockade. J Nanobiotechnol 23(1):94, 94","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"5966_CR88","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s13046-023-02770-6","volume":"42","author":"T Nakazawa","year":"2023","unstructured":"Nakazawa T, Morimoto T, Maeoka R, Matsuda R, Nakamura M, Nishimura F, Ouji N, Yamada S, et al. (2023) CIS deletion by CRISPR\/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma. J Exp Clin Cancer Res 42(1):205, 205","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"5966_CR89","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.3390\/ijms22073489","volume":"22","author":"T Morimoto","year":"2021","unstructured":"Morimoto T, Nakazawa T, Matsuda R, Nishimura F, Nakamura M, Yamada S, Nakagawa I, Park Y-S, et al. (2021) CRISPR-Cas9\u2013mediated TIM3 knockout in human natural killer cells enhances growth inhibitory effects on human glioma cells. Int J Mol Sci 22(7):3489, 3489","journal-title":"Int J Mol Sci"},{"key":"5966_CR90","doi-asserted-by":"crossref","unstructured":"Saenz-Anto\u00f1anzas A, Moncho-Amor V, Auzmendi-Iriarte J, Elua-Pinin A, Rizzoti K, Lovell-Badge R, Matheu A (2021) CRISPR\/Cas9 deletion of SOX2 regulatory region 2 (SRR2) decreases SOX2 malignant activity in glioblastoma. Cancers (Basel) 13(7):1574","DOI":"10.3390\/cancers13071574"},{"issue":"1","key":"5966_CR91","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12951-025-03182-8","volume":"23","author":"C Zou","year":"2025","unstructured":"Zou C, Liu X, Wang W, He L, Yin A, Cao Z, Zhu M, Wu Y, et al. (2025) Targeting GDF15 to enhance immunotherapy efficacy in glioblastoma through tumor microenvironment-responsive CRISPR-Cas9 nanoparticles. J Nanobiotechnol 23(1):126, 126","journal-title":"J Nanobiotechnol"},{"issue":"32","key":"5966_CR92","doi-asserted-by":"publisher","first-page":"2309314","DOI":"10.1002\/advs.202309314","volume":"11","author":"H Zhang","year":"2024","unstructured":"Zhang H, Jiang W, Song T, Song M, Liu S, Zhou J, Cheng H, Ding Y (2024) Lipid\u2010polymer nanoparticles mediate compartmentalized delivery of Cas9 and sgRNA for glioblastoma vasculature and immune reprogramming. Adv Sci 11(32):2309314, 2309314","journal-title":"Adv Sci"},{"issue":"17","key":"5966_CR93","doi-asserted-by":"publisher","first-page":"16432","DOI":"10.1021\/acsnano.2c12857","volume":"17","author":"X Liu","year":"2023","unstructured":"Liu X, Cao Z, Wang W, Zou C, Wang Y, Pan L, Jia B, Zhang K, et al. (2023) Engineered extracellular vesicle-delivered CRISPR\/Cas9 for radiotherapy sensitization of glioblastoma. ACS Nano 17(17):16432\u201316447","journal-title":"ACS Nano"},{"issue":"12","key":"5966_CR94","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202407262","volume":"12","author":"N Rouatbi","year":"2025","unstructured":"Rouatbi N, Walters AA, Zam A, Lim YM, Marrocu A, Anstee JE, Arnold JN, Wang JTW, et al. (2025) CD47 knock\u2010out using CRISPR\u2010Cas9 RNA lipid nanocarriers results in reduced mesenchymal glioblastoma growth in vivo. Adv Sci 12(12):2407262","journal-title":"Adv Sci"},{"issue":"1","key":"5966_CR95","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ymthe.2024.11.023","volume":"33","author":"L Nieland","year":"2025","unstructured":"Nieland L, Vrijmoet AB, Jetten IW, Rufino-Ramos D, de Reus AJ, Breyne K, Kleinstiver BP, Maguire CA, et al. (2025) CRISPR targeting of mmu-miR-21a through a single adeno-associated virus vector prolongs survival of glioblastoma-bearing mice. Mol Ther 33(1):133\u2013151","journal-title":"Mol Ther"},{"key":"5966_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.bea.2022.100053","volume":"4","author":"T Ahmed","year":"2022","unstructured":"Ahmed T (2022) Neural stem cell engineering for the treatment of multiple sclerosis. Biomed Eng Adv 4:100053","journal-title":"Biomed Eng Adv"},{"key":"5966_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e19763","author":"M Sahlolbei","year":"2023","unstructured":"Sahlolbei M, Azangou-Khyavy M, Khanali J, Khorsand B, Shiralipour A, Ahmadbeigi N, Madjd Z, Ghanbarian H, et al. (2023) Engineering chimeric autoantibody receptor T cells for targeted B cell depletion in multiple sclerosis model: an in-vitro study. Heliyon. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e19763","journal-title":"Heliyon"},{"issue":"9","key":"5966_CR98","doi-asserted-by":"publisher","first-page":"102893","DOI":"10.1016\/j.autrev.2021.102893","volume":"20","author":"M Dema","year":"2021","unstructured":"Dema M, Eixarch H, Villar LM, Montalban X, Espejo (2021) Immunosenescence in multiple sclerosis: the identification of new therapeutic targets. Autoimmun Rev 20(9):102893, 102893","journal-title":"Autoimmun Rev"},{"issue":"9","key":"5966_CR99","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.3390\/biomedicines11092489","volume":"11","author":"L Eva","year":"2023","unstructured":"Eva L, Ple\u0219 H, Covache-Busuioc R-A, Glavan LA, Bratu B-G, Bordeianu A, Dumitrascu D-I, Corlatescu AD, et al. (2023) A comprehensive review on neuroimmunology: insights from multiple sclerosis to future therapeutic developments. Biomedicines 11(9):2489, 2489","journal-title":"Biomedicines"},{"issue":"13","key":"5966_CR100","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.3390\/jcm12134274","volume":"12","author":"Z Khan","year":"2023","unstructured":"Khan Z, Gupta GD, Mehan (2023) Cellular and molecular evidence of multiple sclerosis diagnosis and treatment challenges. J Clin Med 12(13):4274, 4274","journal-title":"J Clin Med"},{"issue":"1","key":"5966_CR101","doi-asserted-by":"publisher","first-page":"6419","DOI":"10.1038\/s41467-024-50794-z","volume":"15","author":"M Pahlevan Kakhki","year":"2024","unstructured":"Pahlevan Kakhki M, Giordano A, Starvaggi Cucuzza C, Samudyata S, Lem\u00e9e MV, Stridh P, Gkogka A, Shchetynsky K, et al. (2024) A genetic-epigenetic interplay at 1q21. 1 locus underlies CHD1L-mediated vulnerability to primary progressive multiple sclerosis. Nat Commun 15(1):6419, 6419","journal-title":"Nat Commun"},{"key":"5966_CR102","doi-asserted-by":"publisher","first-page":"800128","DOI":"10.3389\/fimmu.2021.800128","volume":"12","author":"M Linnerbauer","year":"2021","unstructured":"Linnerbauer M, L\u00f6\u00dflein L, Farrenkopf D, Vandrey O, Tsaktanis T, Naumann U, Rothhammer V (2021) Astrocyte-derived pleiotrophin mitigates late-stage autoimmune CNS inflammation. Front Immunol 12:800128, 800128","journal-title":"Front Immunol"},{"key":"5966_CR103","doi-asserted-by":"crossref","unstructured":"Romero JC, Berlinicke C, Chow S, Duan Y, Wang Y, Chamling X, Smirnova (2023) Oligodendrogenesis and myelination tracing in a CRISPR\/Cas9-engineered brain microphysiological system. Front Cell Neurosci 16:1094291","DOI":"10.3389\/fncel.2022.1094291"},{"issue":"6","key":"5966_CR104","doi-asserted-by":"publisher","first-page":"7661","DOI":"10.1096\/fj.201902966RR","volume":"34","author":"YW Chiu","year":"2020","unstructured":"Chiu YW, Hori Y, Ebinuma I, Sato H, Hara N, Ikeuchi T, Tomita (2020) Identification of calcium and integrin\u2010binding protein 1 as a novel regulator of production of amyloid \u03b2 peptide using CRISPR\/Cas9\u2010based screening system. FASEB J 34(6):7661\u20137674","journal-title":"FASEB J"},{"issue":"8","key":"5966_CR105","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.stem.2024.06.001","volume":"31","author":"N Saurat","year":"2024","unstructured":"Saurat N, Minotti AP, Rahman MT, Sikder T, Zhang C, Cornacchia D, Jungverdorben J, Ciceri G, et al. (2024) Genome-wide CRISPR screen identifies neddylation as a regulator of neuronal aging and AD neurodegeneration. Cell Stem Cell 31(8):1162-1174. e1168","journal-title":"Cell Stem Cell"},{"key":"5966_CR106","doi-asserted-by":"crossref","unstructured":"Lu L, Yu X, Cai Y, Sun M, Yang H (2021) Application of CRISPR\/Cas9 in Alzheimer\u2019s disease. Front Neurosci 15:803894","DOI":"10.3389\/fnins.2021.803894"},{"key":"5966_CR107","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jare.2021.07.001","volume":"40","author":"S Bhardwaj","year":"2022","unstructured":"Bhardwaj S, Kesari KK, Rachamalla M, Mani S, Ashraf GM, Jha SK, Kumar P, Ambasta RK, et al. (2022) CRISPR\/Cas9 gene editing: new hope for Alzheimer\u2019s disease therapeutics. J Adv Res 40:207\u2013221","journal-title":"J Adv Res"},{"issue":"1","key":"5966_CR108","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1038\/s41598-021-82658-7","volume":"11","author":"L Duan","year":"2021","unstructured":"Duan L, Hu M, Tamm JA, Grinberg YY, Shen F, Chai Y, Xi H, Gibilisco L, et al. (2021) Arrayed CRISPR reveals genetic regulators of tau aggregation, autophagy and mitochondria in Alzheimer\u2019s disease model. Sci Rep 11(1):2879, 2879","journal-title":"Sci Rep"},{"issue":"1","key":"5966_CR109","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13024-023-00692-7","volume":"18","author":"P Yeapuri","year":"2023","unstructured":"Yeapuri P, Machhi J, Lu Y, Abdelmoaty MM, Kadry R, Patel M, Bhattarai S, Lu E, et al. (2023) Amyloid-\u03b2 specific regulatory T cells attenuate Alzheimer\u2019s disease pathobiology in APP\/PS1 mice. Mol Neurodegener 18(1):97, 97","journal-title":"Mol Neurodegener"},{"issue":"6","key":"5966_CR110","doi-asserted-by":"publisher","first-page":"e13840","DOI":"10.1111\/acel.13840","volume":"22","author":"L He","year":"2023","unstructured":"He L, Chen Y, Lin S, Shen R, Pan H, Zhou Y, Wang Y, Chen S, et al. (2023) Regulation of Hsa\u2010miR\u20104639\u20105p expression and its potential role in the pathogenesis of Parkinson\u2019s disease. Aging Cell 22(6):e13840","journal-title":"Aging Cell"},{"issue":"8","key":"5966_CR111","first-page":"e67037","volume":"16","author":"WS Roberts","year":"2024","unstructured":"Roberts WS, Price S, Wu M, Parmar (2024) Emerging gene therapies for Alzheimer\u2019s and Parkinson\u2019s diseases: an overview of clinical trials and promising candidates. Cureus 16(8):e67037","journal-title":"Cureus"},{"key":"5966_CR112","first-page":"1","volume":"2024","author":"R Mathur","year":"2024","unstructured":"Mathur R, Seamon (2024) CRISPR technology for Parkinson\u2019s disease: recent advancements and ongoing challenges. STEM Fellowsh J 2024:1\u201310","journal-title":"STEM Fellowsh J"},{"key":"5966_CR113","doi-asserted-by":"publisher","first-page":"101795","DOI":"10.1016\/j.redox.2020.101795","volume":"38","author":"D-H Gou","year":"2021","unstructured":"Gou D-H, Huang T-T, Li W, Gao X-D, Haikal C, Wang X-H, Song D-Y, Liang X, et al. (2021) Inhibition of copper transporter 1 prevents \u03b1-synuclein pathology and alleviates nigrostriatal degeneration in AAV-based mouse model of Parkinson\u2019s disease. Redox Biol 38:101795, 101795","journal-title":"Redox Biol"},{"issue":"2","key":"5966_CR114","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4103\/mgmj.mgmj_90_20","volume":"8","author":"CE Okechukwu","year":"2021","unstructured":"Okechukwu CE (2021) Deciphering and manipulating the epigenome for the treatment of Parkinson\u2019s and Alzheimer\u2019s disease. MGM J Med Sci 8(2):171\u2013186","journal-title":"MGM J Med Sci"},{"issue":"6","key":"5966_CR115","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.3390\/pharmaceutics14061252","volume":"14","author":"MU Rahman","year":"2022","unstructured":"Rahman MU, Bilal M, Shah JA, Kaushik A, Teissedre P-L, Kujawska M (2022) CRISPR-Cas9-based technology and its relevance to gene editing in Parkinson\u2019s disease. Pharmaceutics 14(6):1252, 1252","journal-title":"Pharmaceutics"},{"issue":"1","key":"5966_CR116","doi-asserted-by":"publisher","first-page":"e10367","DOI":"10.1002\/btm2.10367","volume":"8","author":"P Chopade","year":"2023","unstructured":"Chopade P, Chopade N, Zhao Z, Mitragotri S, Liao R, Chandran Suja (2023) Alzheimer\u2019s and Parkinson\u2019s disease therapies in the clinic. Bioeng Transl Med 8(1):e10367","journal-title":"Bioeng Transl Med"},{"issue":"4","key":"5966_CR117","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/mds.27642","volume":"34","author":"RN Alcalay","year":"2019","unstructured":"Alcalay RN, Mallett V, Vanderperre B, Tavassoly O, Dauvilliers Y, Wu RY, Ruskey JA, Leblond CS, et al. (2019) SMPD1 mutations, activity, and \u03b1\u2010synuclein accumulation in Parkinson\u2019s disease. Mov Disord 34(4):526\u2013535","journal-title":"Mov Disord"},{"issue":"6","key":"5966_CR118","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1093\/brain\/awz084","volume":"142","author":"N Kuzumaki","year":"2019","unstructured":"Kuzumaki N, Suda Y, Iwasawa C, Narita M, Sone T, Watanabe M, Maekawa A, Matsumoto T, et al. (2019) Cell-specific overexpression of COMT in dopaminergic neurons of Parkinson\u2019s disease. Brain 142(6):1675\u20131689","journal-title":"Brain"},{"issue":"14","key":"5966_CR119","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1523\/JNEUROSCI.1508-21.2022","volume":"42","author":"C-k Oh","year":"2022","unstructured":"Oh C-k, Dolatabadi N, Cieplak P, Diaz-Meco MT, Moscat J, Nolan JP, Nakamura T, Lipton (2022) S-Nitrosylation of p62 inhibits autophagic flux to promote \u03b1-synuclein secretion and spread in Parkinson\u2019s disease and Lewy body dementia. J Neurosci 42(14):3011\u20133024","journal-title":"J Neurosci"},{"issue":"3","key":"5966_CR120","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/epi4.12941","volume":"9","author":"\u0160 Dana\u010d\u00edkov\u00e1","year":"2024","unstructured":"Dana\u010d\u00edkov\u00e1 \u0160, Straka B, Dan\u011bk J, Ko\u0159\u00ednek V, Ot\u00e1hal (2024) In vitro human cell culture models in a bench\u2010to\u2010bedside approach to epilepsy. Epilepsia Open 9(3):865\u2013890","journal-title":"Epilepsia Open"},{"key":"5966_CR121","doi-asserted-by":"crossref","unstructured":"Zhao C, Rollo B, Javaid MS, Huang Z, He W, Xu H, Kwan P, Zhang C (2024) An integrated in vitro human iPSCs-derived neuron and in vivo animal approach for preclinical screening of anti-seizure compounds. J Adv Res 64:249\u2013262","DOI":"10.1016\/j.jare.2023.11.022"},{"issue":"9","key":"5966_CR122","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.3390\/brainsci13091305","volume":"13","author":"S Ghosh","year":"2023","unstructured":"Ghosh S, Sinha JK, Ghosh S, Sharma H, Bhaskar R, Narayanan (2023) A comprehensive review of emerging trends and innovative therapies in epilepsy management. Brain Sci 13(9):1305, 1305","journal-title":"Brain Sci"},{"key":"5966_CR123","doi-asserted-by":"crossref","unstructured":"Anurogo D (2021) Stem cells and gene therapy in epilepsy management. JKKI: Jurnal Kedokteran dan Kesehatan Indonesia\u00a0103\u2013106","DOI":"10.20885\/JKKI.Vol12.Iss2.art1"},{"issue":"12","key":"5966_CR124","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/s41582-020-0409-4","volume":"16","author":"R Nabbout","year":"2020","unstructured":"Nabbout R, Kuchenbuch MIop (2020) Impact of predictive, preventive and precision medicine strategies in epilepsy. Nat Rev Neurol 16(12):674\u2013688","journal-title":"Nat Rev Neurol"},{"key":"5966_CR125","doi-asserted-by":"crossref","unstructured":"Boileau C, Deforges S, Peret A, Scavarda D, Bartolomei F, Giles A, Partouche N, Gautron J, et al. (2023) GluK2 is a target for gene therapy in drug\u2010resistant temporal lobe epilepsy. Ann Neurol 94(4):745\u2013761","DOI":"10.1002\/ana.26723"},{"issue":"1","key":"5966_CR126","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s11033-024-09215-z","volume":"51","author":"T Liu","year":"2024","unstructured":"Liu T, Liu H, Xue S, Xiao L, Xu J, Tong S, Wei X (2024) MiR129-5p-loaded exosomes suppress seizure-associated neurodegeneration in status epilepticus model mice by inhibiting HMGB1\/TLR4-mediated neuroinflammation. Mol Biol Rep 51(1):292","journal-title":"Mol Biol Rep"},{"issue":"5","key":"5966_CR127","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3390\/biomedicines9050470","volume":"9","author":"S Ghosh","year":"2021","unstructured":"Ghosh S, Sinha JK, Khan T, Devaraju KS, Singh P, Vaibhav K, Gaur (2021) Pharmacological and therapeutic approaches in the treatment of epilepsy. Biomedicines 9(5):470, 470","journal-title":"Biomedicines"},{"key":"5966_CR128","doi-asserted-by":"publisher","first-page":"1213969","DOI":"10.3389\/fneur.2023.1213969","volume":"14","author":"C Miguel Sanz","year":"2023","unstructured":"Miguel Sanz C, Martinez Navarro M, Caballero Diaz D, Sanchez-Elexpuru G, Di Donato (2023) Toward the use of novel alternative methods in epilepsy modeling and drug discovery. Front Neurol 14:1213969, 1213969","journal-title":"Front Neurol"},{"key":"5966_CR129","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.omtn.2019.10.042","volume":"19","author":"TN Zamay","year":"2020","unstructured":"Zamay TN, Zamay GS, Shnayder NA, Dmitrenko DV, Zamay SS, Yushchenko V, Kolovskaya OS, Susevski V, et al. (2020) Nucleic acid aptamers for molecular therapy of epilepsy and blood-brain barrier damages. Mol Ther Nucleic Acids 19:157\u2013167","journal-title":"Mol Ther Nucleic Acids"},{"key":"5966_CR130","first-page":"24","volume":"10","author":"Y Pathak","year":"2022","unstructured":"Pathak Y (2022) Recent trends and advancements in experimental epilepsy therapeutics. EC Pharmacol Toxicol 10:24\u201333","journal-title":"EC Pharmacol Toxicol"},{"key":"5966_CR131","doi-asserted-by":"crossref","unstructured":"Tang BL (2016) K+-cl\u2212 co-transporter 2 (KCC2)\u2013a membrane trafficking perspective.\u00a0Mol Membr Biol 33(6\u20138):100\u2013110","DOI":"10.1080\/09687688.2017.1393566"},{"issue":"6","key":"5966_CR132","doi-asserted-by":"publisher","first-page":"459","DOI":"10.37349\/ent.2024.00094","volume":"4","author":"L Radenovic","year":"2024","unstructured":"Radenovic L (2024) Exploring therapeutical targets and innovative treatments for ischemic stroke: a comprehensive review. Explor Neuroprotect Ther 4(6):459\u2013484","journal-title":"Explor Neuroprotect Ther"},{"key":"5966_CR133","doi-asserted-by":"crossref","unstructured":"Bakka AG, Patil SS, Rachakonda B, Patil A, Bolleddula J, Nandyala PSKR, Singamaneni R, Sade N, Patnaik PK (2025) Breaking barriers in stroke therapy: recent advances and ongoing challenges. Cureus\u00a017(1):e78288","DOI":"10.7759\/cureus.78288"},{"key":"5966_CR134","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.jconrel.2020.10.064","volume":"330","author":"Y Lee","year":"2021","unstructured":"Lee Y, Lee J, Kim M, Kim G, Choi JS, Lee M (2021) Brain gene delivery using histidine and arginine-modified dendrimers for ischemic stroke therapy. J Control Release 330:907\u2013919","journal-title":"J Control Release"},{"key":"5966_CR135","doi-asserted-by":"publisher","DOI":"10.1177\/20417314241237052","volume":"15","author":"S-Y Lei","year":"2024","unstructured":"Lei S-Y, Yang Y-Q, Liu J-C, Zhang D-H, Qu Y, Sun Y-Y, Zhu H-J, Zhou S-Y, et al. (2024) Nanodrug delivery systems for regulating microglial polarization in ischemic stroke treatment: a review. J Tissue Eng 15:20417314241237052","journal-title":"J Tissue Eng"},{"issue":"10","key":"5966_CR136","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.4103\/1673-5374.390957","volume":"19","author":"M Yuan","year":"2024","unstructured":"Yuan M, Tang Y, Huang T, Ke L, Huang (2024) In situ direct reprogramming of astrocytes to neurons via polypyrimidine tract-binding protein 1 knockdown in a mouse model of ischemic stroke. Neural Regen Res 19(10):2240\u20132248","journal-title":"Neural Regen Res"},{"issue":"1","key":"5966_CR137","doi-asserted-by":"publisher","first-page":"188582","DOI":"10.1016\/j.bbcan.2021.188582","volume":"1876","author":"B Nowak","year":"2021","unstructured":"Nowak B, Rogujski P, Janowski M, Lukomska B, Andrzejewska (2021) Mesenchymal stem cells in glioblastoma therapy and progression: how one cell does it all. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1876(1):188582, 188582","journal-title":"Biochimica et Biophysica Acta (BBA)-Reviews on Cancer"},{"issue":"7","key":"5966_CR138","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3390\/cells14070494","volume":"14","author":"J Tang","year":"2025","unstructured":"Tang J, Karbhari N, Campian JTtigmp (2025) Therapeutic targets in glioblastoma: molecular pathways, emerging strategies, and future directions. Cells 14(7):494, 494","journal-title":"Cells"},{"issue":"5","key":"5966_CR139","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10406","volume":"8","author":"R Tamura","year":"2023","unstructured":"Tamura R, Miyoshi H, Imaizumi K, Yo M, Kase Y, Sato T, Sato M, Morimoto Y, et al. (2023) Gene therapy using genome\u2010edited iPS cells for targeting malignant glioma. Bioeng Transl Med 8(5):e10406","journal-title":"Bioeng Transl Med"},{"issue":"13","key":"5966_CR140","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.3390\/cancers13133152","volume":"13","author":"JH Park","year":"2021","unstructured":"Park JH, de Lomana ALG, Marzese DM, Juarez T, Feroze A, Hothi P, Cobbs C, Patel AP, et al. (2021) A systems approach to brain tumor treatment. Cancers 13(13):3152, 3152","journal-title":"Cancers"},{"issue":"4","key":"5966_CR141","doi-asserted-by":"publisher","first-page":"686","DOI":"10.20517\/cdr.2020.38","volume":"3","author":"RA Towner","year":"2020","unstructured":"Towner RA, Zalles M, Saunders D, Smith (2020) Novel approaches to combat chemoresistance against glioblastomas. Cancer Drug Resist 3(4):686, 686","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"5966_CR142","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/neuonc\/noq142","volume":"13","author":"U Bogdahn","year":"2010","unstructured":"Bogdahn U, Hau P, Stockhammer G, Venkataramana N, Mahapatra A, Suri A, Balasubramaniam A, Nair S, et al. (2010) Targeted therapy for high-grade glioma with the TGF-\u03b22 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro-oncol 13(1):132\u2013142","journal-title":"Neuro-oncol"},{"issue":"4","key":"5966_CR143","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040998","volume":"9","author":"T Nakazawa","year":"2020","unstructured":"Nakazawa T, Natsume A, Nishimura F, Morimoto T, Matsuda R, Nakamura M, Yamada S, Nakagawa I, et al. (2020) Effect of CRISPR\/Cas9-mediated PD-1-disrupted primary human third-generation CAR-T cells targeting EGFRvIII on in vitro human glioblastoma cell growth. Cells 9(4):998","journal-title":"Cells"},{"issue":"4","key":"5966_CR144","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","volume":"30","author":"CE Brown","year":"2024","unstructured":"Brown CE, Hibbard JC, Alizadeh D, Blanchard MS, Natri HM, Wang D, Ostberg JR, Aguilar B, et al. (2024) Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat Med 30(4):1001\u20131012","journal-title":"Nat Med"},{"issue":"6","key":"5966_CR145","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/nan.12639","volume":"46","author":"MV Petkova","year":"2020","unstructured":"Petkova MV, Stantzou A, Morin A, Petrova O, Morales-Gonzalez S, Seifert F, Bellec-Dyevre J, Manoliu T, et al. (2020) Live-imaging of revertant and therapeutically restored dystrophin in the DmdEGFP-mdx mouse model for Duchenne muscular dystrophy. Neuropathol Appl Neurobiol 46(6):602\u2013614","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"29","key":"5966_CR146","first-page":"01","volume":"13","author":"KG Raju","year":"2024","unstructured":"Raju KG, Goud PV, Parween S, Ramarao M, Leelavati T, Madhavi S, Aminabee S (2024) Economic analysis of pharmacological interventions for substance use disorders cost-effectiveness and market dynamics. Ashdin Publishing Journal of Drug and Alcohol Research 13(29):01\u201304","journal-title":"Ashdin Publishing Journal of Drug and Alcohol Research"},{"key":"5966_CR147","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.omtn.2017.02.007","volume":"7","author":"P Zhu","year":"2017","unstructured":"Zhu P, Wu F, Mosenson J, Zhang H, He T-C, Wu W-S (2017) CRISPR\/Cas9-mediated genome editing corrects dystrophin mutation in skeletal muscle stem cells in a mouse model of muscle dystrophy. Mol Ther Nucleic Acids 7:31\u201341","journal-title":"Mol Ther Nucleic Acids"},{"key":"5966_CR148","doi-asserted-by":"crossref","unstructured":"Aminabee S, Chaitanya MMSN, Begum MA, Jonnalagadda SK, Devi MS, Thanmai P\u00a0(2025) Gene editing in neurological disorders: role of CRISPR-Cas9 in targeted therapies. Biomed Pharmacol J\u00a018(October Spl Edition):844-55","DOI":"10.13005\/bpj\/3396"},{"key":"5966_CR149","first-page":"11","volume":"7","author":"A Lattanzi","year":"2017","unstructured":"Lattanzi A, Duguez S, Moiani A, Izmiryan A, Barbon E, Martin S, Mamchaoui K, Mouly V, et al. (2017) Correction of the exon 2 duplication in DMD myoblasts by a single CRISPR\/Cas9 system. Mol Ther 7:11\u201319","journal-title":"Mol Ther"},{"key":"5966_CR150","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1398089","volume":"15","author":"CE Kvistad","year":"2024","unstructured":"Kvistad CE, Kr\u00e5kenes T, Gavasso S, B\u00f8 L (2024) Neural regeneration in the human central nervous system\u2014from understanding the underlying mechanisms to developing treatments. Where do we stand today? Front Neurol 15:1398089","journal-title":"Front Neurol"},{"key":"5966_CR151","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2022.01.013","volume":"342","author":"EA Taha","year":"2022","unstructured":"Taha EA, Lee J, Hotta (2022) Delivery of CRISPR-Cas tools for in vivo genome editing therapy: trends and challenges. J Control Release 342:345\u2013361","journal-title":"J Control Release"},{"issue":"7","key":"5966_CR152","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.3390\/ijms24076373","volume":"24","author":"X Zhao","year":"2023","unstructured":"Zhao X, Jacob (2023) Mechanisms of demyelination and remyelination strategies for multiple sclerosis. Int J Mol Sci 24(7):6373, 6373","journal-title":"Int J Mol Sci"},{"issue":"12","key":"5966_CR153","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.3390\/biomedicines11123333","volume":"11","author":"A Klinkovskij","year":"2023","unstructured":"Klinkovskij A, Shepelev M, Isaakyan Y, Aniskin D, Ulasov (2023) Advances of genome editing with CRISPR\/Cas9 in neurodegeneration: the right path towards therapy. Biomedicines 11(12):3333, 3333","journal-title":"Biomedicines"},{"issue":"6","key":"5966_CR154","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3390\/ph17060763","volume":"17","author":"E BenDavid","year":"2024","unstructured":"BenDavid E, Ramezanian S, Lu Y, Rousseau J, Schroeder A, Lavertu M, Tremblay (2024) Emerging perspectives on prime editor delivery to the brain. Pharmaceuticals (Basel) 17(6):763, 763","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"5966_CR155","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40291-023-00687-6","volume":"28","author":"B Bettegazzi","year":"2024","unstructured":"Bettegazzi B, Cattaneo S, Simonato M, Zucchini S, Soukupova M (2024) Viral vector-based gene therapy for epilepsy: what does the future hold? Mol Diagn Ther 28(1):5\u201313","journal-title":"Mol Diagn Ther"},{"key":"5966_CR156","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jconrel.2022.08.014","volume":"350","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Conniot J, Amorim J, Jin Y, Prasad R, Yan X, Fan K, Conde J (2022) Nucleic acid-based therapy for brain cancer: challenges and strategies. J Control Release 350:80\u201392","journal-title":"J Control Release"},{"issue":"11","key":"5966_CR157","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1016\/j.ymthe.2018.08.010","volume":"26","author":"BL Duch\u00eane","year":"2018","unstructured":"Duch\u00eane BL, Cherif K, Iyombe-Engembe J-P, Guyon A, Rousseau J, Ouellet DL, Barbeau X, Lague P, et al. (2018) CRISPR-induced deletion with SaCas9 restores dystrophin expression in dystrophic models in vitro and in vivo. Mol Ther 26(11):2604\u20132616","journal-title":"Mol Ther"},{"issue":"1","key":"5966_CR158","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.xphs.2019.10.003","volume":"109","author":"A Mehta","year":"2020","unstructured":"Mehta A, Merkel OMJ (2020) Immunogenicity of Cas9 protein. J Pharm Sci 109(1):62\u201367","journal-title":"J Pharm Sci"},{"key":"5966_CR159","doi-asserted-by":"crossref","unstructured":"Manghwar H, Li B, Ding X, Hussain A, Lindsey K, Zhang X, Jin SJ (2020) CRISPR\/Cas systems in genome editing: methodologies and tools for sgRNA design, off-target evaluation, and strategies to mitigate off-target effects.\u00a0Adv Sci 7(6):1902312","DOI":"10.1002\/advs.201902312"},{"issue":"7723","key":"5966_CR160","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s41586-018-0500-9","volume":"561","author":"P Akcakaya","year":"7723","unstructured":"Akcakaya P, Bobbin ML, Guo JA, Malagon-Lopez J, Clement K, Garcia SP, Fellows MD, Porritt MJ, et al. (7723) In vivo CRISPR editing with no detectable genome-wide off-target mutations. Nature 561(7723):416\u2013419","journal-title":"Nature"},{"key":"5966_CR161","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2015.37","author":"X-H Zhang","year":"2015","unstructured":"Zhang X-H, Tee LY, Wang X-G, Huang Q-S, Yang S-H (2015) Off-target effects in CRISPR\/Cas9-mediated genome engineering. Mol Ther. https:\/\/doi.org\/10.1038\/mtna.2015.37","journal-title":"Mol Ther"},{"key":"5966_CR162","doi-asserted-by":"publisher","first-page":"122855","DOI":"10.1016\/j.lfs.2024.122855","volume":"352","author":"J Shang","year":"2024","unstructured":"Shang J, Song F, Zhang Z, Chen D, Yang SAonCtibt (2024) Application of novel CRISPR tools in brain therapy. Life Sci 352:122855, 122855","journal-title":"Life Sci"},{"issue":"26","key":"5966_CR163","doi-asserted-by":"publisher","first-page":"2201740","DOI":"10.1002\/advs.202201740","volume":"9","author":"M Luo","year":"2022","unstructured":"Luo M, Lee LKC, Peng B, Choi CHJ, Tong WY, Voelcker (2022) Delivering the promise of gene therapy with nanomedicines in treating central nervous system diseases. Adv Sci 9(26):2201740, 2201740","journal-title":"Adv Sci"},{"key":"5966_CR164","doi-asserted-by":"publisher","first-page":"113943","DOI":"10.1016\/j.biopha.2022.113943","volume":"156","author":"A Hazrati","year":"2022","unstructured":"Hazrati A, Malekpour K, Soudi S, Hashemi SM (2022) CRISPR\/Cas9-engineered mesenchymal stromal\/stem cells and their extracellular vesicles: a new approach to overcoming cell therapy limitations. Biomed Pharmacother 156:113943, 113943","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"5966_CR165","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3390\/cells11010116","volume":"11","author":"N Attia","year":"2021","unstructured":"Attia N, Mashal M, Pemminati S, Omole A, Edmondson C, Jones W, Priyadarshini P, Mughal T, et al. (2021) Cell-based therapy for the treatment of glioblastoma: an update from preclinical to clinical studies. Cells 11(1):116, 116","journal-title":"Cells"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-05966-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-026-05966-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-05966-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T13:03:52Z","timestamp":1781096632000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-026-05966-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":165,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5966"],"URL":"https:\/\/doi.org\/10.1007\/s12035-026-05966-x","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"26 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"686"}}